TWI648063B - 用於免疫以對抗艱難梭菌（Ｃ. difficile）之組合物及方法 - Google Patents
用於免疫以對抗艱難梭菌（Ｃ. difficile）之組合物及方法 Download PDFInfo
- Publication number
- TWI648063B TWI648063B TW103120772A TW103120772A TWI648063B TW I648063 B TWI648063 B TW I648063B TW 103120772 A TW103120772 A TW 103120772A TW 103120772 A TW103120772 A TW 103120772A TW I648063 B TWI648063 B TW I648063B
- Authority
- TW
- Taiwan
- Prior art keywords
- toxoid
- day
- difficile
- toxin
- administration
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims abstract description 128
- 239000000203 mixture Substances 0.000 title claims description 123
- 238000000034 method Methods 0.000 title abstract description 43
- 230000003053 immunization Effects 0.000 title description 5
- 238000002649 immunization Methods 0.000 title description 3
- 101710182223 Toxin B Proteins 0.000 claims abstract description 94
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims abstract description 90
- 101710182532 Toxin a Proteins 0.000 claims abstract description 90
- 230000028993 immune response Effects 0.000 claims abstract description 72
- 208000015181 infectious disease Diseases 0.000 claims abstract description 48
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 230000001939 inductive effect Effects 0.000 claims abstract description 5
- 239000002671 adjuvant Substances 0.000 claims description 56
- 230000003472 neutralizing effect Effects 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 12
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 230000009885 systemic effect Effects 0.000 claims description 9
- 229910052782 aluminium Inorganic materials 0.000 claims description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229940088710 antibiotic agent Drugs 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 230000002045 lasting effect Effects 0.000 claims description 5
- 210000002346 musculoskeletal system Anatomy 0.000 claims description 5
- 210000002345 respiratory system Anatomy 0.000 claims description 5
- 230000002485 urinary effect Effects 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 62
- 238000002965 ELISA Methods 0.000 description 44
- 238000004458 analytical method Methods 0.000 description 44
- 239000000427 antigen Substances 0.000 description 39
- 108091007433 antigens Proteins 0.000 description 39
- 102000036639 antigens Human genes 0.000 description 39
- 239000003053 toxin Substances 0.000 description 33
- 231100000765 toxin Toxicity 0.000 description 33
- 108700012359 toxins Proteins 0.000 description 33
- 238000009472 formulation Methods 0.000 description 29
- 238000002255 vaccination Methods 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 13
- 230000002163 immunogen Effects 0.000 description 12
- 230000005847 immunogenicity Effects 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 206010067484 Adverse reaction Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000006838 adverse reaction Effects 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 8
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001147 anti-toxic effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 229940044601 receptor agonist Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108010049048 Cholera Toxin Proteins 0.000 description 3
- 102000009016 Cholera Toxin Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108010081690 Pertussis Toxin Proteins 0.000 description 3
- -1 Ringer's solutions Chemical compound 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 231100000279 safety data Toxicity 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 229920006318 anionic polymer Polymers 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012931 lyophilized formulation Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000007793 ph indicator Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000032537 response to toxin Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 159000000004 beryllium salts Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- ZDSXRJABOCTJTD-HUYBTDLASA-N butyl (2r)-2-[[(2s)-2-[[(2r)-2-[(3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoate Chemical compound CCCCOC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O ZDSXRJABOCTJTD-HUYBTDLASA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229950009571 murabutide Drugs 0.000 description 1
- 108700017543 murabutide Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000026416 response to pain Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003970 toll like receptor agonist Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 201000002516 toxic megacolon Diseases 0.000 description 1
- 229940031572 toxoid vaccine Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361835246P | 2013-06-14 | 2013-06-14 | |
| US61/835,246 | 2013-06-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201536314A TW201536314A (zh) | 2015-10-01 |
| TWI648063B true TWI648063B (zh) | 2019-01-21 |
Family
ID=51168412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103120772A TWI648063B (zh) | 2013-06-14 | 2014-06-16 | 用於免疫以對抗艱難梭菌（Ｃ. difficile）之組合物及方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9730994B2 (enExample) |
| EP (1) | EP3007724B1 (enExample) |
| JP (1) | JP6691477B2 (enExample) |
| KR (1) | KR20160020543A (enExample) |
| CN (1) | CN105611942A (enExample) |
| AU (1) | AU2014277981B2 (enExample) |
| BR (1) | BR112015031088A2 (enExample) |
| CA (1) | CA2915279A1 (enExample) |
| MX (1) | MX2015017257A (enExample) |
| SG (1) | SG11201510166YA (enExample) |
| TW (1) | TWI648063B (enExample) |
| WO (1) | WO2014201346A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR086199A1 (es) | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| SG11201510166YA (en) | 2013-06-14 | 2016-01-28 | Sanofi Pasteur Inc | Compositions and methods of immunizing against c. difficile |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MX2020003756A (es) * | 2017-09-28 | 2020-07-29 | Pfizer | Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile. |
| WO2021255690A2 (en) | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071759A (en) | 1986-05-30 | 1991-12-10 | The United States Of America As Represented By The Secretary Of The Army | Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B |
| US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| EP2305303A3 (en) | 1997-10-20 | 2013-11-13 | Sanofi Pasteur Biologics Co. | Immunization against Clostridium difficile disease |
| AU2008299885C1 (en) * | 2007-09-14 | 2015-06-25 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing clostridium difficile toxoids A and B |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| AR086199A1 (es) | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| GB201206070D0 (en) | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| HK1213917A1 (zh) | 2013-03-15 | 2016-07-15 | Sanofi Pasteur, Inc. | 類霉素、組合物及相關方法 |
| KR20150133770A (ko) * | 2013-03-15 | 2015-11-30 | 사노피 파스퇴르 인코포레이티드 | 톡소이드, 조성물 및 관련 방법 |
| SG11201510166YA (en) | 2013-06-14 | 2016-01-28 | Sanofi Pasteur Inc | Compositions and methods of immunizing against c. difficile |
-
2014
- 2014-06-13 SG SG11201510166YA patent/SG11201510166YA/en unknown
- 2014-06-13 JP JP2016519675A patent/JP6691477B2/ja active Active
- 2014-06-13 CA CA2915279A patent/CA2915279A1/en not_active Abandoned
- 2014-06-13 AU AU2014277981A patent/AU2014277981B2/en not_active Ceased
- 2014-06-13 BR BR112015031088A patent/BR112015031088A2/pt not_active Application Discontinuation
- 2014-06-13 MX MX2015017257A patent/MX2015017257A/es unknown
- 2014-06-13 EP EP14737429.2A patent/EP3007724B1/en active Active
- 2014-06-13 US US14/897,870 patent/US9730994B2/en active Active
- 2014-06-13 WO PCT/US2014/042298 patent/WO2014201346A1/en not_active Ceased
- 2014-06-13 KR KR1020167001130A patent/KR20160020543A/ko not_active Ceased
- 2014-06-13 CN CN201480044768.7A patent/CN105611942A/zh active Pending
- 2014-06-16 TW TW103120772A patent/TWI648063B/zh not_active IP Right Cessation
-
2017
- 2017-07-10 US US15/645,057 patent/US20170304423A1/en not_active Abandoned
-
2019
- 2019-10-21 US US16/658,278 patent/US20200113991A1/en not_active Abandoned
-
2021
- 2021-01-08 US US17/144,486 patent/US11419930B2/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Greenberg, Richard N., et al. "Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine." Vaccine 30.13 (2012): 2245-2249. * |
| Kotloff, Karen L., et al. "Safety and Immunogenicity of Increasing Doses of a Clostridium difficile Toxoid Vaccine Administered to Healthy Adults." Infection and immunity 69.2 (2001): 988-995. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20170304423A1 (en) | 2017-10-26 |
| US20210145956A1 (en) | 2021-05-20 |
| WO2014201346A1 (en) | 2014-12-18 |
| EP3007724A1 (en) | 2016-04-20 |
| JP6691477B2 (ja) | 2020-04-28 |
| BR112015031088A2 (pt) | 2017-07-25 |
| US20200113991A1 (en) | 2020-04-16 |
| US11419930B2 (en) | 2022-08-23 |
| US9730994B2 (en) | 2017-08-15 |
| KR20160020543A (ko) | 2016-02-23 |
| US20160120968A1 (en) | 2016-05-05 |
| TW201536314A (zh) | 2015-10-01 |
| JP2016521754A (ja) | 2016-07-25 |
| MX2015017257A (es) | 2016-11-11 |
| CN105611942A (zh) | 2016-05-25 |
| CA2915279A1 (en) | 2014-12-18 |
| SG11201510166YA (en) | 2016-01-28 |
| AU2014277981A1 (en) | 2016-01-07 |
| AU2014277981B2 (en) | 2019-06-20 |
| EP3007724B1 (en) | 2023-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11419930B2 (en) | Compositions and methods for immunizing against C. difficile | |
| US20230062987A1 (en) | Methods and compositions for immune protection against extra-intestinal pathogenic e. coli | |
| Neimert-Andersson et al. | Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I/IIa clinical trial | |
| RU2723045C2 (ru) | Композиции neisseria meningitidis и способы их получения | |
| US20250312432A1 (en) | Compositions and methods for eliciting an immune response against clostridium difficile | |
| US20140335536A1 (en) | Vaccine for the treatment of mycobaterium related disorders | |
| US20210261651A1 (en) | Compositions and methods for treating inflammatory bowel disease | |
| WO2026067038A1 (zh) | 一种用于预防或治疗破伤风的联合疫苗 | |
| Dagan et al. | Safety and immunogenicity of a new formulation of an inactivated hepatitis A vaccine | |
| Jarosova et al. | Effects of oil-based adjuvants on the immune response of pigs after dermal administration of antigen and evaluation of the immunization level after a subsequent Actinobacillus pleuropneumoniae challenge in pigs | |
| CN110507819B (zh) | 青蒿琥酯作为免疫佐剂在制备狂犬病疫苗中的应用 | |
| MacDonald et al. | Efficacy of a single dose hepatitis B depot vaccine | |
| US20210220459A1 (en) | Vaccine compositions | |
| TW202612726A (zh) | 誘發針對困難梭狀芽孢桿菌的免疫反應之免疫原性組成物和方法 | |
| US20220313816A1 (en) | Compositions and methods for antibody-as-adjuvant vaccines and therapeutics | |
| EP2892552A1 (en) | An immunogenic composition comprising an inactivated recombinant non-pathogenic bacterium | |
| KR20230091978A (ko) | 면역원성 항원 | |
| EA045827B1 (ru) | Иммуногенные композиции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |